GRANULES Stock Overview
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, and internationally.
No risks detected for GRANULES from our risk checks.
Granules India Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹317.30|
|52 Week High||₹404.80|
|52 Week Low||₹280.50|
|1 Month Change||3.09%|
|3 Month Change||-2.44%|
|1 Year Change||-9.01%|
|3 Year Change||240.09%|
|5 Year Change||175.08%|
|Change since IPO||2,946.57%|
Recent News & Updates
These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
|GRANULES||IN Pharmaceuticals||IN Market|
Return vs Industry: GRANULES underperformed the Indian Pharmaceuticals industry which returned 9.5% over the past year.
Return vs Market: GRANULES underperformed the Indian Market which returned 34.4% over the past year.
|GRANULES Average Weekly Movement||5.4%|
|Pharmaceuticals Industry Average Movement||6.0%|
|Market Average Movement||6.7%|
|10% most volatile stocks in IN Market||9.9%|
|10% least volatile stocks in IN Market||4.1%|
Stable Share Price: GRANULES is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: GRANULES's weekly volatility (5%) has been stable over the past year.
About the Company
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other specialty products for oncology.
Granules India Fundamentals Summary
|GRANULES fundamental statistics|
Is GRANULES overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GRANULES income statement (TTM)|
|Cost of Revenue||₹16.28b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||19.16|
|Net Profit Margin||14.05%|
How did GRANULES perform over the long term?See historical performance and comparison
0.5%Current Dividend Yield
Is Granules India undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GRANULES (₹317.3) is trading below our estimate of fair value (₹380.67)
Significantly Below Fair Value: GRANULES is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: GRANULES is good value based on its PE Ratio (16.6x) compared to the Indian Pharmaceuticals industry average (25.9x).
PE vs Market: GRANULES is good value based on its PE Ratio (16.6x) compared to the Indian market (23.4x).
Price to Earnings Growth Ratio
PEG Ratio: GRANULES is good value based on its PEG Ratio (0.7x)
Price to Book Ratio
PB vs Industry: GRANULES's PB Ratio (3.3x) is in line with the IN Pharmaceuticals industry average.
How is Granules India forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GRANULES's forecast earnings growth (23.7% per year) is above the savings rate (6.7%).
Earnings vs Market: GRANULES's earnings (23.7% per year) are forecast to grow faster than the Indian market (20.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GRANULES's revenue (17.2% per year) is forecast to grow faster than the Indian market (13.2% per year).
High Growth Revenue: GRANULES's revenue (17.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GRANULES's Return on Equity is forecast to be high in 3 years time (20.8%)
How has Granules India performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GRANULES has high quality earnings.
Growing Profit Margin: GRANULES's current net profit margins (14.1%) are lower than last year (14.9%).
Past Earnings Growth Analysis
Earnings Trend: GRANULES's earnings have grown significantly by 31.2% per year over the past 5 years.
Accelerating Growth: GRANULES's earnings growth over the past year (10.2%) is below its 5-year average (31.2% per year).
Earnings vs Industry: GRANULES earnings growth over the past year (10.2%) underperformed the Pharmaceuticals industry 29.7%.
Return on Equity
High ROE: GRANULES's Return on Equity (20.1%) is considered high.
How is Granules India's financial position?
Financial Position Analysis
Short Term Liabilities: GRANULES's short term assets (₹22.1B) exceed its short term liabilities (₹14.1B).
Long Term Liabilities: GRANULES's short term assets (₹22.1B) exceed its long term liabilities (₹3.5B).
Debt to Equity History and Analysis
Debt Level: GRANULES's net debt to equity ratio (25.7%) is considered satisfactory.
Reducing Debt: GRANULES's debt to equity ratio has reduced from 76% to 40.8% over the past 5 years.
Debt Coverage: GRANULES's debt is well covered by operating cash flow (48.9%).
Interest Coverage: GRANULES's interest payments on its debt are well covered by EBIT (84.9x coverage).
What is Granules India current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GRANULES's dividend (0.47%) is higher than the bottom 25% of dividend payers in the Indian market (0.3%).
High Dividend: GRANULES's dividend (0.47%) is low compared to the top 25% of dividend payers in the Indian market (1.33%).
Stability and Growth of Payments
Stable Dividend: GRANULES's dividends per share have been stable in the past 10 years.
Growing Dividend: GRANULES's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (7.8%), GRANULES's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GRANULES's dividends in 3 years are forecast to be thoroughly covered by earnings (4.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Krishna Chigurupati (67 yo)
Dr. Krishna Prasad Chigurupati, B.Sc. had been Managing Director of Granules India Limited since September 1, 2009. He serves as Chairman of Granules India Limited and has been its Non-Independent Executiv...
CEO Compensation Analysis
Compensation vs Market: Krishna's total compensation ($USD5.62M) is above average for companies of similar size in the Indian market ($USD352.52K).
Compensation vs Earnings: Krishna's compensation has increased by more than 20% in the past year.
Experienced Management: GRANULES's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: GRANULES's board of directors are considered experienced (8.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Granules India Limited's employee growth, exchange listings and data sources
- Name: Granules India Limited
- Ticker: GRANULES
- Exchange: NSEI
- Founded: 1984
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹78.667b
- Shares outstanding: 248.01m
- Website: https://www.granulesindia.com
Number of Employees
- Granules India Limited
- My Home Hub
- 2nd Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 15:46|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.